Drug Trial Radar · NCT06645691
Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 17, 2024
Primary completion
May 31, 2028
Study completion May 31, 2028
Sponsor
- Lead sponsor
- National Heart Centre SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Medical Research Council (NMRC), Singapore
- First posted
- Oct 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years, up to 99 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.
Conditions
- Heart Failure
- Cardiometabolic Syndrome
- Cancer Diagnosis
- Cardiovascular Diseases
- Healthy Volunteers
Interventions
Hyperpolarized 13C-pyruvateDrug
Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility and reproducibility of Imaging TechniqueTime frame: 30 - 45 minutes post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Heart Centre Singapore
Singapore, Singapore · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.